Haofan Biotech (301393.SZ) announced its first-half results, with net profit of 707.463 million yuan to mother, a year-on-year decrease of 6.77%

According to the Zhitong Finance App, Haofan Biotech (301393.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of 379 million yuan, an increase of 40.30% over the previous year. Net profit attributable to shareholders of listed companies was 707.463 million yuan, a year-on-year decrease of 6.77%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 60.3799 million yuan, a year-on-year decrease of 2.61%. Basic earnings per share were $0.66.

During the reporting period, revenue increased by 40.30% year-on-year, mainly due to the company's competitive advantage, seizing market opportunities, making concerted efforts to resolve production capacity bottlenecks, deeply meeting customer needs, and achieving steady growth in performance. By product, sales revenue of peptide synthesis reagents was 264.1092 million yuan, up 19.32% year on year, sales revenue of general-purpose molecular blocks was 53.02 million yuan, up 78.40% year on year, and sales revenue of protein reagents was 27.662 million yuan, up 63.92% year on year.